Swiss Re is forecasting long-term mortality improvement trends for insurance. The company’s latest report, “The Future of life expectancy” shows that although, gains in human longevity have tapered off over the last decade, the next wave of improvements is on its way.
A health worker is disinfected at an Ebola treatment centre in Beni, Eastern Congo (AP Photo/Al-hadji Kudra Maliro)
Life expectancy improvements typically come in waves following major medical breakthroughs or large-scale social trends according to history. In the twentieth century, pharmaceutical innovations which lowered blood pressure and cholesterol triggered a steep improvement in life expectancy. The global average life expectancy for a person born in 2020 is over 70 years, compared with only 55 years at the end of the 1950s.
However, since 2010, factors such as obesity-related diseases, the growing impact of Alzheimer’s, and unequal access to health care have chipped at life expectancy gains in many parts of the world resulting in life expectancies levelling off in advanced markets.
Paul Murray, Swiss Re’s CEO of L&H Reinsurance, said, “While people continue to dream of life expectancy surpassing 100 years, the gains of the last century are under threat. Clearly, medical research has the power to drive the next big wave of improvements in longevity. However, individuals need to maintain and intensify their healthy lifestyle choices to ensure they live longer and healthier lives. As a society, we need to address barriers to healthcare access.”
Advances in cancer diagnosis and treatment are the most likely areas to improve global longevity, according to the report. Future improvements will need to be supported by addressing older-age health issues such as Alzheimer’s, lifestyle factors and access to healthcare.
As of 2019, only the top 10% of the US population by socioeconomic status have a comparable life expectancy at birth to the OECD average of around 80 years for men and 84 years for women. For a US male born into the lowest 10% by socioeconomic status, life expectancy is around 73 years comparatively. The trend makes the US diverge from other advanced markets.
The trend is linked to unequal access to healthcare as a result of growing socioeconomic inequality. With an estimated 70% of the population affected by obesity, diseases such as type 2 diabetes are becoming more prevalent and opioid-related deaths have impacted life expectancy, with an eightfold increase since 1999.
Between 1968 and 2010, about 70% of the UK’s longevity improvement was credited to substantial reductions in circulatory disease-related deaths. Causing a rise in life expectancy from 71 to 80 years. However, since 2010, life expectancy in the UK has increased by only one year. Since there were fewer advances in cancer treatments and the increasing impact of dementia and respiratory diseases the previous gains in longevity have dampened.
Japan and Switzerland achieved some of the highest life expectancies at birth in advanced economies, averaging around 84 years in both countries. This is an improvement from around 70 years in 1960, primarily due to improved cardiovascular health. Lifestyle factors and access to well-funded healthcare systems have supported their success. For example, Japan’s efforts to reduce stroke-related deaths by over 80% between 1980 and 2012 are noteworthy, as this was achieved by relatively straightforward measures, such as encouraging people to reduce salt in their diets.
According to Swiss Re’s report, advances in cancer treatments and diagnosis have the highest potential to kickstart life expectancy improvements. For example, liquid biopsies can offer earlier detection for certain types of cancer. Meanwhile, the shift from more general therapies to personalised, precision medicines, is expected to improve survival rates. Additionally, the use of mRNA vaccines, which were successfully deployed during the COVID-19 pandemic, is an area of potential improvement.
Natalie Kelly, the Head of Global Underwriting, Claims & R&D at Swiss Re said, “Medical technology, lifestyle changes and access to healthcare will propel the next wave of longevity improvements. The public and private sectors both have roles to play. For the insurance industry, it is vital that we understand these complex drivers so we can continue to protect customers when they need it most and encourage people to make lifestyle choices that support longer healthier lives.”
In the UK, the high uptake for screening for some cancers has been shown to improve survivability by well over 50%. Addressing diseases which affect people later in life will be key to extending lifespans, especially Alzheimer’s and other causes of dementia. Projections in the UK, see the number of those affected by Alzheimer’s nearly doubling to over 1.6 million by 2040. Currently, few therapies offer more than symptomatic relief and medical developments in this area have been relatively slow, with controversial results for some proposed treatments.
Several emerging technologies may have a large effect on life expectancy. The arrival of artificial intelligence in medical research and in guiding treatment decisions as well as wearable devices and apps to monitor an individual’s health or well-being can deliver future improvements.
